• Release your full potential

    Be free to be active. Pioneering new territory to set new standards

ABOUT US

MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Read more about MC2 Therapeutics.

Platform

We apply our expertise in formulation and clinical practice to ensure treatment satisfaction for the patients and release of the full clinical potential of therapies.

When topical dosage form is considered the right dosage form, our PAD Technology™ formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for immune-mediated and inflammatory conditions. Read more about our platform.

Pipeline

With a holistic focus on patient care, we develop OTC skincare products specifically designed to complement medical treatments and provide soothing relief for dry, itchy skin caused by inflammation. Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-07

MC2 Therapeutics Announces License and Commercialization Agreement for Wynzora® Cream in Canada

Copenhagen, November 14, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE

CEO Jesper J. Lange awarded as CEO of the Year

On June 18th, 2024 our CEO, Jesper J. Lange, received the award ...

READ FULL ARTICLE

 

mc2_news-image-icon-07

MC2 Therapeutics Receives Positive Feedback from FDA pre-IND Meeting and Updates on Indication Expansion Strategy

  • On track to file IND in mid-2025 for a Phase 2b clinical trial in Hidradenitis Suppurativa ...

    READ FULL ARTICLE

mc2_news-image-icon-05

MC2 Therapeutics Announces License, Supply and Commercialization Agreement for Wynzora® Cream in ASEAN Countries

Copenhagen, March 12th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE